Division of Gynecologic Oncology, The Mount Sinai School of Medicine, New York, NY 10029, USA.
Gynecol Oncol. 2010 Feb;116(2):286-9. doi: 10.1016/j.ygyno.2009.11.012.
Uterine serous carcinoma (USC) is an aggressive endometrial cancer associated with poor prognosis despite comprehensive surgical staging and adjuvant chemotherapy and radiation therapy. Biologic targets have yet to be fully explored in this disease and research on such targets could lead to clinical trials utilizing a new class of therapeutics.
A MEDLINE search of molecular alterations in USC was performed and reviewed.
Studies evaluating primary USC tumors for molecular alterations have focused on molecules such as the transmembrane receptor ERBB2 (HER-2), the epidermal growth factor receptor (EGFR), and the recently characterized oncogene PIK3CA, which encodes the catalytic p110-alpha subunit of phosphatidylinositol 3-kinase (PI3K). In addition, claudin-3 and claudin-4 have recently been shown to be highly expressed in USC and have potential utilization as tumor markers and possible target proteins.
Since optimal treatment of uterine serous carcinoma remains unknown, novel therapeutic approaches need to be actively pursued. The molecular targets discussed warrant further investigation and suggest a potential role for therapeutic agents targeting HER-2 and EGFR, as well as downstream targets such as the PI3K-AKT-mTOR pathway in the treatment of uterine serous carcinoma.
子宫浆液性癌（USC）是一种侵袭性子宫内膜癌，尽管进行了全面的手术分期以及辅助化疗和放疗，但预后仍较差。在这种疾病中，尚未充分探索生物靶点，对这些靶点的研究可能会导致利用新一类治疗药物进行临床试验。
对 USC 中分子改变进行了 MEDLINE 搜索并进行了综述。
评估原发性 USC 肿瘤分子改变的研究集中在跨膜受体 ERBB2（HER-2）、表皮生长因子受体（EGFR）和最近被描述的癌基因 PIK3CA 等分子上，后者编码磷脂酰肌醇 3-激酶（PI3K）的催化 p110-α亚基。此外，Claudin-3 和 Claudin-4 最近被证明在 USC 中高度表达，可能作为肿瘤标志物和潜在的靶蛋白。
由于子宫浆液性癌的最佳治疗方法仍不清楚，因此需要积极探索新的治疗方法。所讨论的分子靶标值得进一步研究，并提示针对 HER-2 和 EGFR 以及下游靶标（如 PI3K-AKT-mTOR 通路）的治疗药物可能在治疗子宫浆液性癌中发挥作用。
